Frequency of Hymenoptera-stings in Patients Under Allergen-Specific Immunotherapy (SIT)
Completed
- Conditions
- Hymenoptera Sting Allergy
- Registration Number
- NCT00742794
- Lead Sponsor
- University of Zurich
- Brief Summary
In Switzerland, 3.5% of the population are suffering from hymenoptera venom allergy. The only causal treatment of hymenoptera alelrty is venom specific immunotherapy. There are however several reasons, which question the relatively broad application of this expensive treatment. That's why we aim at investigating the actual risk for hymenoptera stings in patients undergoing allergen specific immunotherapy against hymenoptera sting allergy
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie venom-specific immunotherapy's impact on Hymenoptera sting frequency in allergic patients?
How does allergen-specific immunotherapy compare to standard-of-care treatments in reducing Hymenoptera sting risk in Switzerland?
Are there biomarkers that predict adherence or response to venom immunotherapy in Hymenoptera allergy patients?
What adverse events are associated with venom-specific immunotherapy and how are they managed in clinical practice?
What socio-economic factors influence the efficacy of Hymenoptera venom immunotherapy in reducing sting incidents?